Lyu Ming, Cui Ying, Zhao Tiechan, Ning Zhaochen, Ren Jie, Jin Xingpiao, Fan Guanwei, Zhu Yan
Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Research and Development Center of TCM, Tianjin International Joint Academy of Biomedicine, Tianjin, China.
Front Pharmacol. 2018 Apr 6;9:312. doi: 10.3389/fphar.2018.00312. eCollection 2018.
Shuxuening injection (SXNI) is a widely prescribed herbal medicine of Ginkgo biloba extract (EGB) for cerebral and cardiovascular diseases in China. However, its curative effects on ischemic stroke and heart diseases and the underlying mechanisms remain unknown. Taking an integrated approach of RNA-seq and network pharmacology analysis, we compared transcriptome profiles of brain and heart ischemia reperfusion injury in C57BL/6J mice to identify common and differential target genes by SXNI. Models for myocardial ischemia reperfusion injury (MIRI) by ligating left anterior descending coronary artery (LAD) for 30 min ischemia and 24 h reperfusion and cerebral ischemia reperfusion injury (CIRI) by middle cerebral artery occlusion (MCAO) for 90 min ischemia and 24 h reperfusion were employed to identify the common mechanisms of SXNI on both cerebral and myocardial ischemia reperfusion. In the CIRI model, ischemic infarct volume was markedly decreased after pre-treatment with SXNI at 0.5, 2.5, and 12.5 mL/kg. In the MIRI model, pre-treatment with SXNI at 2.5 and 12.5 mL/kg improved cardiac function and coronary blood flow and decreased myocardial infarction area. Besides, SXNI at 2.5 mL/kg also markedly reduced the levels of LDH, AST, CK-MB, and CK in serum. RNA-seq analysis identified 329 differentially expressed genes (DEGs) in brain and 94 DEGs in heart after SXNI treatment in CIRI or MIRI models, respectively. Core analysis by Ingenuity Pathway Analysis (IPA) revealed that atherosclerosis signaling and inflammatory response were top-ranked in the target profiles for both CIRI and MIRI after pre-treatment with SXNI. Specifically, was recognized as an important common target, and was regulated by SXNI in CIRI and MIRI. In conclusion, our study showed that SXNI effectively protects brain and heart from I/R injuries via a common -mediated pathway involving atherosclerosis signaling and inflammatory response. It provides a novel knowledge of active ingredients of Ginkgo biloba on cardio-cerebral vascular diseases in future clinical application.
舒血宁注射液(SXNI)是中国广泛用于治疗心脑血管疾病的一种银杏叶提取物(EGB)草药制剂。然而,其对缺血性中风和心脏病的疗效及潜在机制尚不清楚。我们采用RNA测序和网络药理学分析相结合的方法,比较了C57BL/6J小鼠脑和心脏缺血再灌注损伤的转录组图谱,以确定舒血宁注射液作用的共同和差异靶基因。采用结扎左冠状动脉前降支(LAD)30分钟缺血和24小时再灌注建立心肌缺血再灌注损伤(MIRI)模型,以及大脑中动脉闭塞(MCAO)90分钟缺血和24小时再灌注建立脑缺血再灌注损伤(CIRI)模型,以确定舒血宁注射液对脑和心肌缺血再灌注的共同作用机制。在CIRI模型中,用0.5、2.5和12.5 mL/kg的舒血宁注射液预处理后,缺血梗死体积明显减小。在MIRI模型中,用2.5和12.5 mL/kg的舒血宁注射液预处理可改善心脏功能和冠状动脉血流量,并减小心肌梗死面积。此外,2.5 mL/kg的舒血宁注射液还显著降低了血清中LDH、AST、CK-MB和CK的水平。RNA测序分析分别在CIRI或MIRI模型中舒血宁注射液治疗后,在脑中鉴定出329个差异表达基因(DEGs),在心脏中鉴定出94个DEGs。通过Ingenuity Pathway Analysis(IPA)进行的核心分析表明,在舒血宁注射液预处理后的CIRI和MIRI的靶标图谱中,动脉粥样硬化信号传导和炎症反应排名靠前。具体而言,[此处原文缺失具体基因名称]被认为是一个重要的共同靶点,并且在CIRI和MIRI中受舒血宁注射液调节。总之,我们的研究表明,舒血宁注射液通过涉及动脉粥样硬化信号传导和炎症反应的共同[此处原文缺失具体介导物名称]介导途径,有效保护脑和心脏免受缺血/再灌注损伤。它为银杏叶在未来临床应用中心脑血管疾病的活性成分提供了新的认识。